Research and Drug Trials

Issues concerning developments in care of Ocular Inflammatory Disease and other noteworthy Items are contained in this forum.

Moderators: Mike Bartolatz, kwork

Post Reply
Mike Bartolatz
Posts: 6595
Joined: Fri Feb 06, 2004 9:58 pm

Research and Drug Trials

Post by Mike Bartolatz » Tue Apr 14, 2009 6:09 pm

http://www.uveitis.org/researchprojects.htm

the above link mentions drug trials in uveitis being done at the Mass. Eye Research and Surgery Institute, the clinc affiliated with the Ocular Immunology and Uveitis Foundation.
Mike Bartolatz
Moderator

Mike Bartolatz
Posts: 6595
Joined: Fri Feb 06, 2004 9:58 pm

Re: Research and Drug Trials

Post by Mike Bartolatz » Tue May 19, 2009 1:30 pm

an IL17 blocking drug is currently in study for uveitis. "so far so good is the response by Dr Foster," at the Ocular Immunology and Uveitis Foundation.

Lets hope there are no adverse side effects and that they produce long term remission from Uveitis and related disease processes.
current study details at the OIUF below:

"Novartis

A new proof-of-concept study has been introduced to our site, sponsored by Novartis. The purpose of this study is to determine safety of AIN457 in patients with uveitis and to determine whether an antibody like AIN457 that neutralizes the cytokine IL-17A will safely reduce the intraocular inflammation associated with non-infections uveitis. Site selection was competitive for the 1 year long study and enrollment to this infusion study is now officially open at our site.'

http://www.clinicaltrials.gov/ct2/show? ... 457&rank=3
clinical trials at various locations in the USA


Mike
Mike Bartolatz
Moderator

Mike Bartolatz
Posts: 6595
Joined: Fri Feb 06, 2004 9:58 pm

Re: Research and Drug Trials

Post by Mike Bartolatz » Tue May 19, 2009 4:20 pm

http://www.faqs.org/patents/app/20080199460

Patent title: Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
Mike Bartolatz
Moderator

Mike Bartolatz
Posts: 6595
Joined: Fri Feb 06, 2004 9:58 pm

Re: Research and Drug Trials

Post by Mike Bartolatz » Tue May 19, 2009 9:16 pm

Mike Bartolatz
Moderator

Mike Bartolatz
Posts: 6595
Joined: Fri Feb 06, 2004 9:58 pm

Re: Research and Drug Trials

Post by Mike Bartolatz » Tue May 19, 2009 9:16 pm

Mike Bartolatz
Moderator

joblack23
Posts: 6
Joined: Tue Jul 08, 2008 9:32 pm

Re: Research and Drug Trials

Post by joblack23 » Sat Jun 06, 2009 12:41 pm

This started to piss me off. Going on 10 years now with occurrence just about every year (sometimes twice). Last year, based on this forum recommendation I went ahead and went nuts. Needless to say after one week in the hospital and $30,000 later the doctors could not identified anything wrong other then valley fever. I did just about every test including MRIs, spinal fluid, close to 20 blood tests. I've even tested for HBL27 (or whatever that thing is called) but eventually it came back negative (false positive for the first time).

Although very unprofessional I’ve seen the local Arizona so called iritis specialist. After a few sessions I realized she has nothing for me other then Pred Forte treatments.

Anything new that the doctors might have found during this past 12 months? Any new drugs that might have shed some light on this pesty disease?

Thanks for everyone's help.

Mike Bartolatz
Posts: 6595
Joined: Fri Feb 06, 2004 9:58 pm

Re: Research and Drug Trials

Post by Mike Bartolatz » Mon Jun 08, 2009 9:38 am

Valley fever is linked to uveitis so that might be your cause.
you might consider seeing a specialist in Salt Lake City, Dr Albert Vitale. his contact information can be found at http://www.uveitis.org in the PATIENT information section of the site on the Specialist list.

Wish you the best,
Mike
Mike Bartolatz
Moderator

Mike Bartolatz
Posts: 6595
Joined: Fri Feb 06, 2004 9:58 pm

Re: Research and Drug Trials

Post by Mike Bartolatz » Wed Jun 17, 2009 9:15 am

AIN457 clinical trials at various locations within the United states.
this is An IL17 blocking drug.
still recruiting individuals with Chronic uveitis in all segments of the eye related to Autoimmune Ocular Inflammatory Disease and uveitis related to various systemic conditions


http://www.clinicaltrials.gov/ct2/show? ... 457&rank=3
Mike Bartolatz
Moderator

Mike Bartolatz
Posts: 6595
Joined: Fri Feb 06, 2004 9:58 pm

Optiquel phase I trial at NEI

Post by Mike Bartolatz » Wed Oct 21, 2009 1:21 pm

NIH and Enzo Biochem to Conduct Clinical Trial with Optiquel
Wed. September 23, 2009; Posted: 09:54 PM
You too can increase your ETF trading!
Sep 24, 2009 (Close-Up Media via COMTEX) -- ENZ | Quote | Chart | News | PowerRating -- Enzo Biochem, Inc. has announced that it had entered into a Cooperative Research and Development Agreement (CRADA) with the National Eye Institute, part of the National Institute of Health, to conduct a human clinical trial of Optiquel, Enzo's oral, proprietary therapeutic for chronic autoimmune uveitis.
Under the terms of the CRADA, Enzo will supply its proprietary compound, Optiquel, and will fund a portion of the studies. The clinical trial will be conducted to assess the safety and efficacy of Optiquel in a proof-of-concept clinical trial designed as a randomized, double-masked, placebo-controlled study with a long-term follow-up. The agreement additionally includes non clinical research focusing on the use of various compounds that may serve to enhance the immune mediated oral tolerance response to specific antigens. Such research may be applicable across the entire spectrum of the Company's immune regulation platform, including Alequel, and EGS21, its therapeutic candidates for the treatment of Crohn's Disease and NASH, respectively.

Robert Nussenblatt, MD, Chief of NEI's Laboratory of Immunology, will serve as the Principal Investigator on this project. According to the group, Dr Nussenblatt, an ocular immunologist and expert in clinical research design and conduct, has authored or co-authored over 400 publications and a number of books, including a standard text on uveitis.

An autoimmune disorder is a malfunction of the immune system which causes it to attack itself. In autoimmune uveitis, the body's own immune system attacks the uvea of the eye, the portion of the eye that lies between the outermost and innermost layers of the eye. Uveitis occurs most frequently in people ages 20 to 50. A recent study estimated that more than 280,000 people in the United States are affected by uveitis each year, and the disease is associated with 30,000 cases of blindness annually.

Patients with chronic autoimmune uveitis are currently treated with general immunosuppressive agents such as steroids. The aim of immunosuppression is to control inflammation and to preserve visual acuity. However, immunosuppression therapy is frequently associated with significant adverse effects, including ocular toxicity (glaucoma and cataract), that limit the duration and intensity of treatment. Therefore, there exists an urgent need for new, non-general and specific therapeutic approaches with less material side effects.

Optiquel has been designed as such a therapeutic approach as it specifically targets the HLA proteins. A Phase I study of Optiquel showed no treatment related side effects. Optiquel therapy is based on oral tolerance, an immunologic mechanism that down-regulates immune responses in an antigen-specific manner, rather than a non-specific immunosuppressive approach. A Phase I study of Optiquel demonstrated a therapeutic effect with no treatment-related side effects. Optiquel has been awarded orphan drug status in the European Union and it is anticipated that a similar designation will be applied for in the US. Enzo has exclusive rights to both US and international patents claiming the use of this compound for the treatment of uveitis.

Enzo said that it will sponsor an investigational new drug (IND) application and submit it to the FDA. Additionally, Enzo has completed all of the bulk manufacturing, stability studies, pharmacokinetics evaluations, and formulation in capsules, as well as prepared the necessary documentation to treat patients. Toxicity studies have all proven negative.

Enzo Biochem is engaged in the research, development, manufacture and licensing of health care products and technologies based on molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community.

((Comments on this story may be sent to health@closeupmedia.com))

For full details on Enzo Biochem Inc (ENZ) click here. Enzo Biochem Inc (ENZ) has Short Term PowerRatings of 7. Details on Enzo Biochem Inc (ENZ) Short Term PowerRatings is available at This Link.
Mike Bartolatz
Moderator

Post Reply